Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
82 hedge funds and large institutions have $2.65B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 17 closing their positions.
288% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $2.99M
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
93% more capital invested
Capital invested by funds: $1.37B → $2.65B (+$1.28B)
32% more funds holding
Funds holding: 62 → 82 (+20)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.3M |
| 2 |
BlackRock
New York
|
+$22.3M |
| 3 |
Alkeon Capital Management
New York
|
+$12.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.4M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$4.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$15.1M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$12.9M |
| 3 |
AG
Artal Group
Luxembourg
|
-$7.16M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.79M |
| 5 |
Bank of New York Mellon
New York
|
-$6.42M |
CERE Hedge Fund Activity: Q2 2021 in Review
82 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q2 2021, worth a combined $2.65B — up 93% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CERE positions and 17 closed out — a net gain of 20 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.3M. The largest seller was Ally Bridge Group, cutting an estimated $15.1M.
- 82 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q2 2021, up from 62 in Q1 2021.
- Funds reported $2.65B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q2 2021, up 93% quarter-over-quarter.
- 37 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q2 2021 and 17 closed out, a net change of +20 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q2 2021 was Fidelity Investments, an estimated $53.3M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q2 2021 was Ally Bridge Group, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2021.